Newsletter | January 8, 2026

01.08.26 -- What 2025 FDA Warning Letters Tell Us About GMP Compliance

INDUSTRY INSIGHTS

Manufacturing Made More Robust And Customer-Centric

Discover how regional manufacturing, risk-aware practices, and agile strategies are reshaping supply chains to deliver resilience, transparency, and sustainability in today’s complex global environment.

FEATURED EDITORIAL

The Module Type Package Wants All Your Equipment To Start Talking

A forthcoming ISPE guide uses case studies to aid in the design of plug-and-play process skids with implications for every step in the manufacturing process continuum.

Unpacking The EU's Mutual Recognition Agreements For Pharma

MRAs can save resources for regulators and drug makers by, among other things, reducing the number of inspections and waiving retesting requirements.

What 2025 FDA Warning Letters Tell Us About GMP Compliance

This analysis identifies key compliance trends and regional disparities by examining the 2025 U.S. FDA warning letters issued to drug product manufacturers posted between Jan. 1 and Dec. 9, 2025.

SOLUTIONS

A Single-Use, Automated Depth Filtration System